



SAFETY DATA SHEET

Revision date: 27-Sep-2018

Version: 3.1

Page 1 of 12

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Tolterodine Tartrate Modified Release Capsules

Trade Name: Detrol LA; Detrusitol LA; Detrol SR, Detrusitol SR; Santizor; Santizor XL; Tolterodin Pfizer; Urotrol Neo

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used for overactive bladder

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 2

Label Elements

Signal Word: Warning
Hazard Statements: H361d - Suspected of damaging the unborn child

Precautionary Statements: P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations



SAFETY DATA SHEET

**Material Name: Tolterodine Tartrate Modified Release
Capsules**
Revision date: 27-Sep-2018

Page 2 of 12

Version: 3.1

Other Hazards An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Starch	9005-25-8	232-679-6	Not Listed	*
Tolterodine L-Tartrate	124937-52-6	Not Listed	Repr. 2 (H361d) Aquatic Acute 2 (H401) Aquatic Chronic 2 (H411)	2
Propylene glycol	57-55-6	200-338-0	Not Listed	*
Titanium dioxide	13463-67-7	236-675-5	Not Listed	*
Oleic acid	112-80-1	204-007-1	Not Listed	*
Sucrose	57-50-1	200-334-9	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Hydroxypropyl methylcellulose	9004-65-3	Not Listed	Not Listed	*
Ethylcellulose	9004-57-3	Not Listed	Not Listed	*
Medium Chain Fatty Acid Triglyceride	Unassigned	Not Listed	Not Listed	*
Ferric oxide yellow	51274-00-1	257-098-5	Not Listed	*
Shellac	9000-59-3	232-549-9	Not Listed	*
Simethicone	8050-81-5	Not Listed	Not Listed	*
FD&C Blue No. 2	860-22-0	212-728-8	Not Listed	*
Gelatin	9000-70-8	232-554-6	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin Contact: Wash skin with soap and water. If irritation occurs or persists, get medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

SAFETY DATA SHEET

Material Name: Tolterodine Tartrate Modified Release
Capsules
Revision date: 27-Sep-2018

Page 3 of 12

Version: 3.1

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Emits toxic fumes of carbon monoxide and nitrogen oxide.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Refer to Section 12 - Ecological Information, for information on potential effects on the environment.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

SAFETY DATA SHEET

Material Name: Tolterodine Tartrate Modified Release
Capsules
Revision date: 27-Sep-2018

Page 4 of 12

Version: 3.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Starch

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Czech Republic OEL - TWA	4.0 mg/m ³
Greece OEL - TWA	10 mg/m ³
	5 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	4 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL - TWAs	3 mg/m ³

Tolterodine L-Tartrate

Pfizer OEL TWA-8 Hr:	25µg/m ³
----------------------	---------------------

Propylene glycol

Australia TWA	150 ppm
	474 mg/m ³
	10 mg/m ³
Ireland OEL - TWAs	150 ppm
	470 mg/m ³
	10 mg/m ³
Latvia OEL - TWA	7 mg/m ³
Lithuania OEL - TWA	7 mg/m ³

Titanium dioxide

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Austria OEL - MAKs	5 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Denmark OEL - TWA	6 mg/m ³
Estonia OEL - TWA	5 mg/m ³
France OEL - TWA	10 mg/m ³
Greece OEL - TWA	10 mg/m ³
	5 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
Latvia OEL - TWA	10 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Poland OEL - TWA	10.0 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Romania OEL - TWA	10 mg/m ³

SAFETY DATA SHEET

Material Name: Tolterodine Tartrate Modified Release
Capsules
Revision date: 27-Sep-2018

Page 5 of 12

Version: 3.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Russia OEL - TWA	10 mg/m ³
Spain OEL - TWA	10 mg/m ³
Sweden OEL - TWAs	5 mg/m ³
Switzerland OEL - TWAs	3 mg/m ³
Vietnam OEL - TWAs	6 mg/m ³
	5 mg/m ³

Oleic acid

Bulgaria OEL - TWA	10.0 mg/m ³
--------------------	------------------------

Sucrose

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Estonia OEL - TWA	10 mg/m ³
France OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
Latvia OEL - TWA	5 mg/m ³
Lithuania OEL - TWA	10 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	6 mg/m ³
Spain OEL - TWA	10 mg/m ³

Simethicone

Pfizer Occupational Exposure Band (OEB): OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

Analytical Method:

Analytical method available for tolterodine. Contact Pfizer Inc for further information.

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands:

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes:

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection:

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

SAFETY DATA SHEET

Material Name: Tolterodine Tartrate Modified Release
Capsules
Revision date: 27-Sep-2018

Page 6 of 12

Version: 3.1

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Capsule	Color:	No data available.
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility: No data available
Water Solubility: No data available
pH: No data available.
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)

Gelatin

No data available

FD&C Blue No. 2

No data available

Ethylcellulose

No data available

Hydroxypropyl methylcellulose

No data available

Medium Chain Fatty Acid Triglyceride

No data available

Oleic acid

No data available

Starch

No data available

Sucrose

No data available

Shellac

No data available

Titanium dioxide

No data available

Simethicone

No data available

Ferric oxide yellow

No data available

Propylene glycol

No data available

Tolterodine L-Tartrate

Predicted Log P 5.24

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

SAFETY DATA SHEET

Material Name: Tolterodine Tartrate Modified Release
Capsules
Revision date: 27-Sep-2018

Page 7 of 12

Version: 3.1

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.
Short Term: Accidental ingestion may cause effects similar to those seen in clinical use.
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on fetus.
Known Clinical Effects: May cause effects similar to those seen in clinical use including dry mouth, blurred vision, constipation, and upset stomach.

Acute Toxicity: (Species, Route, End Point, Dose)

FD&C Blue No. 2

Rat Oral LD50 2 g/kg
Mouse Oral LD50 2500mg/kg

Hydroxypropyl methylcellulose

Rat Oral LD50 > 10,000 mg/kg

Sucrose

Rat Oral LD50 29.7 g/kg

Titanium dioxide

Rat Oral LD50 > 7500 mg/kg
Rat Subcutaneous LD50 50 mg/kg

Propylene glycol

Rat Oral LD 50 22,000 mg/kg
Mouse Oral LD 50 24,900mg/kg
Rabbit Dermal LD 50 20,800mg/kg

Tolterodine L-Tartrate

Mouse Oral LD 50 > 200 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Propylene glycol

SAFETY DATA SHEET

Material Name: Tolterodine Tartrate Modified Release
Capsules
Revision date: 27-Sep-2018

Page 8 of 12

Version: 3.1

11. TOXICOLOGICAL INFORMATION

Skin Irritation Rabbit Mild
Eye Irritation Rabbit Mild

Tolterodine L-Tartrate

Skin Irritation Rabbit Non-irritating
Skin Sensitization - GPMT Guinea Pig No effect

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Tolterodine L-Tartrate

26 Week(s) Mouse Oral 10 mg/kg/day NOEL None identified
52 Week(s) Dog Oral 0.5 mg/kg/day NOEL None identified

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Tolterodine L-Tartrate

Reproductive & Fertility-Females Mouse Oral 20 mg/kg/day NOEL No effects at maximum dose
Reproductive & Fertility-Males Mouse Oral 30 mg/kg/day NOEL No effects at maximum dose
Embryo / Fetal Development Mouse Oral 20 mg/kg/day NOEL Embryotoxicity, Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

FD&C Blue No. 2

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Sucrose

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Tolterodine L-Tartrate

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative
In Vivo Chromosome Aberration Human Lymphocytes Negative
In Vivo Micronucleus Mouse Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Tolterodine L-Tartrate

Not specified Mouse Oral 30 mg/kg/day Maximally Tolerated Dose Not carcinogenic

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Titanium dioxide

IARC:

Group 2B (Possibly Carcinogenic to Humans)

12. ECOLOGICAL INFORMATION

Environmental Overview:

This mixture contains material that is toxic to aquatic life. See Aquatic toxicity data of the active ingredient, below:

Toxicity:

SAFETY DATA SHEET

Material Name: Tolterodine Tartrate Modified Release
Capsules
Revision date: 27-Sep-2018

Page 9 of 12

Version: 3.1

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Tolterodine L-Tartrate

Daphnia magna (Water Flea) OECD LC50 48 Hours 1.7 mg/L
Pseudokirchneriella subcapitata (Green Alga) EC50 72 Hours 20 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential:

Partition Coefficient: (Method, pH, Endpoint, Value)

Tolterodine L-Tartrate

Predicted Log P 5.24

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Hydroxypropyl methylcellulose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present

SAFETY DATA SHEET

Material Name: Tolterodine Tartrate Modified Release
Capsules
Revision date: 27-Sep-2018

Page 10 of 12

Version: 3.1

15. REGULATORY INFORMATION

Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	Not Listed
Starch	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-679-6
Tolterodine L-Tartrate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed
Ethylcellulose	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Medium Chain Fatty Acid Triglyceride	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed
Ferric oxide yellow	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	257-098-5
Propylene glycol	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-338-0
Shellac	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-549-9

Simethicone

SAFETY DATA SHEET

Material Name: Tolterodine Tartrate Modified Release
Capsules
Revision date: 27-Sep-2018

Page 11 of 12

Version: 3.1

15. REGULATORY INFORMATION

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Titanium dioxide

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen 9/2/2011 airborne, unbound particles of respirable size
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	236-675-5

Oleic acid

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	204-007-1

FD&C Blue No. 2

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	212-728-8

Gelatin

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-554-6

Sucrose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-334-9

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child
 Hazardous to the aquatic environment, acute toxicity-Cat.2; H401 - Toxic to aquatic life
 Hazardous to the aquatic environment, chronic toxicity-Cat.2; H411 - Toxic to aquatic life with long lasting effects

SAFETY DATA SHEET

Material Name: Tolterodine Tartrate Modified Release

Page 12 of 12

Capsules

Revision date: 27-Sep-2018

Version: 3.1

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients. Publicly available toxicity information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 8 - Exposure Controls / Personal Protection.

Revision date: 27-Sep-2018
Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet